PharmaEngine News
News
0
Ticker
4162.TWO
ISIN
TW0004162003
PharmaEngine Eulerpool News
PharmaEngine Stock News
PharmaEngine is being monitored by journalists and investors worldwide. We gather the latest PharmaEngine news here.
PharmaEngine Stock Press Releases
PharmaEngine regularly publishes news on the company's website that are relevant for investors.
PharmaEngine News 2026
This page contains all current news, analysis and press releases for PharmaEngine stock (4162.TWO, ISIN: TW0004162003). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at PharmaEngine.
PharmaEngine Stock
PharmaEngine PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus.